AroCell’s 2018 Annual Report published

AroCell today announces that the Annual Report for 2018 is now available on the company’s website: www.arocell.com.

The Annual report is available on the following link: arocell.com/årsredovisning-2018

The report is available in Swedish only.

This information was submitted for publication through the agency of Michael Brobjer, April 12, 2019 at 11:30.

Press release Annual report.pdf

For more information:
Michael Brobjer, CEO
Telephone: +46(0)18 50 30 20
E-mail: michael.brobjer@arocell.com

About AroCell
AroCell AB (AROC) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell’s new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein levels in a blood sample. The TK 210™ ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North with Redeye AB as Certified Adviser: Certifiedadviser@redeye.se, +46 (0)8 121 576 90.
For more information; www.arocell.com